Circulating Tumour DNA (ctDNA) Clearance With Neoadjuvant Durvalumab (D) + Tremelimumab (T) + Enfortumab Vedotin (EV) for Cisplatin-Ineligible Treatment of Muscle-Invasive Bladder Cancer(MIBC) From the Safety Run-in Cohort of the Phase 3 VOLGA Trial